Schering-Plough’s Noxafil Clears FDA For Aspergillus Prophylaxis
Executive Summary
Schering-Plough's Noxafil (posaconazole) is the first antifungal approved by FDA for the prevention of invasive fungal infections caused by Aspergillus species
You may also be interested in...
FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
FDA overshot the user fee goal on Schering-Plough's Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate
FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
FDA overshot the user fee goal on Schering-Plough's Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate
Schering-Plough To Hone Its Edge In “Build The Base” Phase
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20